The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 901–1,000 of 1,027
Nair, R. M., Johnson, M. J., Kravitz, K. A., Huded, C. P., Rajeswaran, J., Anabila, M., Blackstone, E. H., Menon, V., Lincoff, A. M., Kapadia, S. R., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019270 · Cited by 61
Virani, S. S., Woodard, L., Akeroyd, J. M., Ramsey, D. J., Ballantyne, C. M., & Petersen, L. A. (2014) · Clinical Cardiology · doi:10.1002/clc.22343 · Cited by 61
Treating Coronary Disease and the Impact of Endothelial Dysfunction
Matsuzawa, Y., Guddeti, R. R., Kwon, T., Lerman, L. O., & Lerman, A. (2014) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2014.10.004 · Cited by 61
Jaumdally, R. J., Goon, P. K. Y., Varma, C., Blann, A. D., & Lip, G. Y. H. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02151.x · Cited by 62
The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease
Kostis, J. B. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6032-4 · Cited by 61
Predictors of Statin Adherence
Mauskop, A., & Borden, W. B. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0221-2 · Cited by 61
Leiter, L. A., Rosenson, R. S., Stein, E. A., Reckless, J. P. D., Schulte, K.-L., Schleman, M. M., Miller, P., Palmer, M. K., & Sosef, F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.001 · Cited by 61
Chaudhry, S. I., Khan, R. F., Chen, J., Dharmarajan, K., Dodson, J. A., Masoudi, F. A., Wang, Y., & Krumholz, H. M. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001197 · Cited by 61
Puri, R., Nissen, S. E., Somaratne, R. M., Cho, L., Kastelein, J. J. P., Ballantyne, C. M., Köenig, W., Anderson, T. J., Yang, J., Kassahun, H., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.019 · Cited by 61
Unstable Angina and Non–ST-Elevation Myocardial Infarction
Cannon, C. P., & Turpie, A. G. G. (2003) · Circulation · doi:10.1161/01.cir.0000072246.69344.2d · Cited by 61
Self-citationAppropriateness of statin prescription in the elderly
Ruscica, M., Macchi, C., Pavanello, C., Corsini, A., Sahebkar, A., & Sirtori, C. R. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.12.011 · Cited by 61
Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study
Pickering, A. N., Hamm, M., Dawdani, A., Hanlon, J. T., Thorpe, C. T., Gellad, W. F., & Radomski, T. R. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16370 · Cited by 61
Karalis, D. G. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60544-2 · Cited by 61
Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?
Bruce, I. N. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.05.001 · Cited by 61
Managing Cardiovascular Risk in Patients With HIV Infection
Stein, J. H. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000147525.26746.07 · Cited by 61
Left ventricular remodeling after myocardial infarction: past, present, and future.
Tiyyagura, S. R., & Pinney, S. (2006) · PubMed · Cited by 61
Mazhar, F., Hjemdahl, P., Clase, C. M., Johnell, K., Jernberg, T., Sjölander, A., & Carrero, J. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025813 · Cited by 60
Preston, R. A., Harvey, P., Herfert, O., Dykstra, G., Jukema, J. W., Sun, F., & Gillen, D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007307879 · Cited by 60
Role of Statins in Coronary Artery Disease
Lim, S. Y. (2013) · Chonnam Medical Journal · doi:10.4068/cmj.2013.49.1.1 · Cited by 60
Statin use in patients with peripheral arterial disease
Harris, S. K., Roos, M. G., & Landry, G. J. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2016.08.094 · Cited by 60
Qaseem, A., Fihn, S. D., Dallas, P., Williams, S., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00011 · Cited by 60
Pfefferkorn, J. A., Choi, C., Larsen, S. D., Auerbach, B. J., Hutchings, R. H., Park, W., Askew, V., Dillon, L., Hanselman, J. C., Lin, Z., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070849r · Cited by 60
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Lindgren, P., Graff, J. S., OLSSON, A. G., Pedersen, T., Jönsson, B., & on behalf of the IDEAL Trial Investigators (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm020 · Cited by 60
Well-Being across the Life Course
Mirowsky, J., & Ross, C. E. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511984945.023 · Cited by 60
Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., et al. (2014) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.04.019 · Cited by 59
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 59
McAfee, A. T., Ming, E. E., Seeger, J. D., Quinn, S. G., Ng, E., Danielson, J. D., Cutone, J. A., Fox, J. C., & Walker, A. M. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1281 · Cited by 59
Stegman, B., Puri, R., Cho, L., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1121 · Cited by 59
The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice
Balcı, B. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960690 · Cited by 59
Statin‐Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction
Ito, M. K., Talbert, R. L., & Tsimikas, S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.7part2.85s · Cited by 59
Milionis, H. J., Moutzouri, E., Kei, & Elisaf, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
Semb, A. G., Holme, I., Kvien, T. K., & Pedersen, T. R. (2010) · Rheumatology · doi:10.1093/rheumatology/keq295 · Cited by 59
Spatz, E. S., Canavan, M., & Desai, M. M. (2009) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.832592 · Cited by 59
Platelet-activating factor acetylhydrolases: An overview and update
Kono, N., & Arai, H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.07.006 · Cited by 59
Did Medicare Part D reduce mortality?
Huh, J., & Reif, J. (2017) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.01.005 · Cited by 59
Intravascular Ultrasound in Cardiovascular Medicine
Nicholls, S. J., Tuzcu, E. M., Sipahi, İ., Schoenhagen, P., & Nissen, S. E. (2006) · Circulation · doi:10.1161/circulationaha.106.637942 · Cited by 59
New evidence on pitavastatin: efficacy and safety in clinical studies
Teramoto, T., Shimano, H., Yokote, K., & Urashima, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003641990 · Cited by 59
Colley, K. J., Wolfert, R. L., & Cobble, M. E. (2011) · The EPMA Journal · doi:10.1007/s13167-011-0063-4 · Cited by 58
Timbie, J. W. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.150 · Cited by 58
KONES, R. J. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710391350 · Cited by 58
Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin
Singh, P., Emami, H., Subramanian, S. S., Maurovich‐Horvat, P., Marincheva-Savcheva, G., Medina, H. M., Abdelbaky, A., Alon, A., Shankar, S. S., Rudd, J. H. F., et al. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.115.004195 · Cited by 58
Safety Issues with Statin Therapy
Talbert, R. L. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506778073637 · Cited by 58
III Diretriz sobre tratamento do infarto agudo do miocárdio
Piegas, L. S., Timerman, A., Nicolau, J. C., Mattos, L. A., Neto, J. M. R., Feitosa, G. S., Avezum, Á., Carvalho, A. C. C., Mansur, A. D. P., Timerman, A., et al. (2004) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2004002200001 · Cited by 58
VersorgungsLeitlinie, N. (2011) · Cited by 58
Li, Y., Wang, Y.-C., Wang, Y., Liu, J., Lee, C., Chen, C., Hsieh, C., Kuo, F. Y., Huang, W., Sung, S., et al. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.06.002 · Cited by 57
Masana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 57
Statins: another class of antihypertensive agents?
Milionis, H. J., Liberopoulos, E. N., Achimastos, A. D., Elisaf, M., & Mikhailidis, D. P. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002001 · Cited by 57
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology
Ray, K. K., & Cannon, C. P. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200412000-00003 · Cited by 57
Self-citationFeinstein, M. J., Jhund, P., Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J., & Lloyd-Jones, D. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.247 · Cited by 56
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein
Kon, V., Yang, H., & Fazio, S. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.05.009 · Cited by 56
Statin Treatment, New-Onset Diabetes, and Other Adverse Effects: A Systematic Review
Bang, C. N., & Okin, P. M. (2014) · Current Cardiology Reports · doi:10.1007/s11886-013-0461-4 · Cited by 56
Javed, U., DEEDWANIA, P. C., Bhatt, D. L., Cannon, C. P., Dai, D., Hernandez, A. F., Peterson, E. D., & Fonarow, G. C. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.12.014 · Cited by 56
Self-citationPetronio, A. S., Amoroso, G., Limbruno, U., Papini, B., Carlo, M. D., Micheli, A., Ciabatti, N., & Mariani, M. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.032 · Cited by 56
Hahn, J., Kim, H.-J., Choi, Y. J., Jo, S., Kim, H. J., Lee, S., Ahn, K.-J., Song, Y. B., Choi, J., Choi, S., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.011 · Cited by 56
Sever, P., Poulter, N. R., Chang, C., Hingorani, A. D., Thom, S., Hughes, A. D., Welsh, P. I., Sattar, N. A., & on behalf of the ASCOT Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr262 · Cited by 56
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 56
Schiele, F., Ecarnot, F., & Chopard, R. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317706586 · Cited by 56
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 56
Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease
Gotto, A. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.059 · Cited by 56
Rossiello, M. R., Momi, S., Caracchini, R., Giannini, S., Guglielmini, G., Monopoli, A., Ongini, E., Semeraro, N., Colucci, M., & Gresele, P. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01605.x · Cited by 56
Messerli, F. H., Bakris, G. L., Ferrera, R. D., Houston, M. C., Petrella, R. J., Flack, J. M., Sun, W. Y., Lee, E., Neutel, J. M., & on behalf of the AVALON Investigators (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05636.x · Cited by 56
A Simplified Approach to the Management of Non–ST-Segment Elevation Acute Coronary Syndromes
Gluckman, T. J. (2005) · JAMA · doi:10.1001/jama.293.3.349 · Cited by 56
Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins
Mason, R. P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.018 · Cited by 56
Lee, S., Lee, Y., Heo, J. H., Hur, S., Choi, H. H., Kim, K.-J., Kim, J. H., Park, K. H., Lee, J. H., Choi, Y. J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.007 · Cited by 55
Baber, U., Gutiérrez, O. M., Levitan, E. B., Warnock, D. G., Farkouh, M. E., Tonelli, M. A., Safford, M. M., & Muntner, P. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.008 · Cited by 55
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors
Pfefferkorn, J. A., Song, Y., Sun, K.-L., Miller, S. R., Trivedi, B. K., Choi, C., Sorenson, R. J., Bratton, L. D., Unangst, P. C., Larsen, S. D., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.096 · Cited by 55
Acute Coronary Syndromes in the Elderly
Engberding, N., & WENGER, N. K. (2017) · F1000Research · doi:10.12688/f1000research.11064.1 · Cited by 55
Sakamoto, T., Kojima, S., Ogawa, H., Shimomura, H., Kimura, K., Ogata, Y., Sakaino, N., Kitagawa, A., & The MUSASHI-AMI Investigators (2007) · Circulation Journal · doi:10.1253/circj.71.1348 · Cited by 55
Surrogate markers for atherosclerotic disease
Sankatsing, R. R., de Groot, E., Jukema, J. W., de Feyter, P. J., Pennell, D. J., Schoenhagen, P., Nissen, S. E., Stroes, E. S. G., & Kastelein, J. J. P. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000174400.68938.f6 · Cited by 55
Lim, S. K., Lee, H., Kimm, K.-C., Park, C., Shin, C., & Cho, N. H. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.02.020 · Cited by 55
Acute management of unstable angina and non-ST segment elevation myocardial infarction
Morita, F., Pesaro, A. E. P., Franken, M., & Wajngarten, M. (2015) · Einstein (São Paulo) · doi:10.1590/s1679-45082015rw3172 · Cited by 54
Lipid-lowering effects of Danhong injection on hyperlipidemia rats
Chen, J., Deng, J., Zhang, Y., Yang, J., He, Y. T., Fu, W., Xing, P., & Wan, H. T. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.04.023 · Cited by 54
Nicholls, S. J., Borgman, M., Nissen, S. E., Raichlen, J. S., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., & Libby, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.570746 · Cited by 54
Ota, H., Omori, H., Kawasaki, M., Hirakawa, A., & Matsuo, H. (2021) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeab034 · Cited by 54
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 54
Dyszkiewicz-Korpanty, A. M., Olteanu, H., Frenkel, E. P., & Sarode, R. (2007) · Platelets · doi:10.1080/09537100701280654 · Cited by 54
Niccoli, G., Biasucci, L. M., Biscione, C., Fusco, B., Porto, I., Leone, A. M., Bona, R. D., Dato, I., Liuzzo, G., & Crea, F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.01.009 · Cited by 54
Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes
Abdel-Maksoud, M. F., Sazonov, V., Gutkin, S. W., & Hokanson, J. E. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318165e2e7 · Cited by 54
Zhou, Z. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041403 · Cited by 54
Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
Masana, L., Plana, N., Andreychuk, N., & Ibarretxe, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106738 · Cited by 53
Gargiulo, P., Basile, C., Galasso, G., Bellino, M., D’Elia, D., Patti, G., Bosco, M., Prinetti, M., Andò, G., Campanella, F., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae170 · Cited by 53
The role of statins in clinical medicine -LDL - cholesterol lowering and beyond
Rutishauser, J. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11170 · Cited by 53
Statins in the Elderly: A Patient‐Focused Approach
Wilmot, K. A., Khan, M. A. S., Krishnan, S. K., Eapen, D. J., & Sperling, L. S. (2014) · Clinical Cardiology · doi:10.1002/clc.22338 · Cited by 53
Atorvastatin: safety and tolerability
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.495385 · Cited by 53
Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments
Digby, J. E., Ruparelia, N., & Choudhury, R. P. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.236315 · Cited by 53
Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
Cai, A., Li, L., Zhang, Y., Mo, Y., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/563717 · Cited by 53
Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303932 · Cited by 53
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.019 · Cited by 53
Modern Management of ST-Segment Elevation Myocardial Infarction
Frampton, J., DeVries, J. T., Welch, T. D., & Gersh, B. J. (2018) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2018.08.005 · Cited by 53
Baumann, A. A. W., Mishra, A., Worthley, M. I., Nelson, A. J., & Psaltis, P. J. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320938527 · Cited by 53
Park, S., Kang, H., Rim, S., Ha, J., Oh, B., Chung, N., & Cho, S.-Y. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.007 · Cited by 53
Pedersen, T. R., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Holme, I., Larsen, M. L., Bendiksen, F. S., Lindahl, C., & Palmer, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.003 · Cited by 53
The Role of Antiphospholipid Syndrome in Cardiovascular Disease
Long, B. R., & Leya, F. S. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.10.002 · Cited by 53
Stone, P. H., Lloyd‐Jones, D. M., Kinlay, S., Frei, B. B., Carlson, W., Rubenstein, J. J., Andrews, T. C., Johnstone, M. T., Sopko, G. S., Cole, H., et al. (2005) · Circulation · doi:10.1161/01.cir.0000160866.90148.76 · Cited by 53
Hochman, J. S., & Steg, P. G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078036 · Cited by 53
Preoperative statin therapy for patients undergoing cardiac surgery
Kuhn, E. W., Slottosch, I., Wahlers, T., & Liakopoulos, O. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008493.pub3 · Cited by 53
RetractedDiabetes and Cardiovascular Disease Prevention in Older Adults
Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50
Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1
Caires-Lima, R., Cayres, K., Protásio, B. M., Caires, I. Q. D. S., Andrade, J., Rocha, L. S. D. S., Takahashi, T. K., Hoff, P. M., de Castro, G., & Mak, M. P. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.831 · Cited by 52
Enriquez, J. R., Pratap, P., Zbilut, J. P., Calvin, J. E., & Volgman, A. S. (2008) · Gender Medicine · doi:10.1016/s1550-8579(08)80008-3 · Cited by 52
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 52
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
